Targeted epigenetic repression of a lymphoma oncogene by sequence-specific histone modifiers induces apoptosis in DLBCL

References

• Stergachis AB, Neph S, Reynolds A, et al. Developmental fate and cellular maturity encoded in human regulatory DNA landscapes. Cell. 2013;154:888–903.
   PubMed Web of Science ®Google Scholar
• Hawkins RD, Larjo A, Tripathi SK, et al. Global chromatin state analysis reveals lineage-specific enhancers during the initiation of human T helper 1 and T helper 2 cell polarization. Immunity. 2013;38:1271–1284.
   PubMed Web of Science ®Google Scholar
• Baylin SB, Jones PA. A decade of exploring the cancer epigenome – biological and translational implications. Nat Rev Cancer. 2011;11:726–734.
   PubMed Web of Science ®Google Scholar
• Koues OI, Kowalewski RA, Chang L-W, et al. Enhancer sequence variants and transcription factor deregulation synergize to construct pathogenic regulatory circuits in B cell lymphoma. Immunity. 2015;42:186–198.
   PubMed Web of Science ®Google Scholar
• Falkenberg KJ, Johnstone RW. Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders. Nat Rev Drug Discov. 2014;13:673–691.
   PubMed Web of Science ®Google Scholar
• Roschewski M, Staudt LM, Wilson WH. Diffuse large B-cell lymphoma-treatment approaches in the molecular era. Nat Rev Clin Oncol. 2014;11:12–23.
   PubMed Web of Science ®Google Scholar
• Sehn LH, Gascoyne RD. Diffuse large B-cell lymphoma: optimizing outcome in the context of clinical and biologic heterogeneity. Blood. 2014;125:22–32.
   PubMed Web of Science ®Google Scholar
• Basso K, Dalla-Favera R. Roles of BCL6 in normal and transformed germinal center B cells. Immunol Rev. 2012;247:172–183.
   PubMed Web of Science ®Google Scholar
• Hatzi K, Melnick A. Breaking bad in the germinal center: how deregulation of BCL6 contributes to lymphomagenesis. Trends Mol Med. 2014;20:343–352.
   PubMed Web of Science ®Google Scholar
• Dent AL. Control of inflammation, cytokine expression, and germinal center formation by BCL-6. Science. 1997;276:589–592.
   PubMed Web of Science ®Google Scholar
• Ye BH, Cattoretti G, Shen Q, et al. The BCL-6 proto-oncogene controls germinal-centre formation and Th2-type inflammation. Nat Genet. 1997;16:161–170.
   PubMed Web of Science ®Google Scholar
• Cattoretti G, Pasqualucci L, Ballon G, et al. Deregulated BCL6 expression recapitulates the pathogenesis of human diffuse large B cell lymphomas in mice. Cancer Cell. 2005;7:445–455.
   PubMed Web of Science ®Google Scholar
• Green MR, Vicente-Dueñas C, Romero-Camarero I, et al. Transient expression of BCL6 is sufficient for oncogenic function and induction of mature B-cell lymphoma. Nat Commun. 2014;5:3904
   PubMed Web of Science ®Google Scholar
• Cerchietti LC, Ghetu AF, Zhu X, et al. A small-molecule inhibitor of BCL6 kills DLBCL cells in vitro and in vivo. Cancer Cell 2010;17:400–411.
   PubMed Web of Science ®Google Scholar
• Ye BH, Lista F, Lo Coco F, et al. Alterations of a zinc finger-encoding gene, BCL-6, in diffuse large-cell lymphoma. Science. 1993;262:747–750.
   PubMed Web of Science ®Google Scholar
• Lenz G, Wright GW, Emre NC, et al. Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways. Proc Natl Acad Sci USA. 2008;105:13520–13525.
   PubMed Web of Science ®Google Scholar
• Wang X, Li Z, Naganuma A, et al. Negative autoregulation of BCL-6 is bypassed by genetic alterations in diffuse large B cell lymphomas. Proc Natl Acad Sci USA. 2002;99:15018–15023.
   PubMed Web of Science ®Google Scholar
• Pasqualucci L, Migliazza A, Basso K, et al. Mutations of the BCL6 proto-oncogene disrupt its negative autoregulation in diffuse large B-cell lymphoma. Blood. 2003;101:2914–2923.
   PubMed Web of Science ®Google Scholar
• Saito M, Gao J, Basso K, et al. A signaling pathway mediating downregulation of BCL6 in germinal center B cells is blocked by BCL6 gene alterations in B cell lymphoma. Cancer Cell. 2007;12:280–292.
   PubMed Web of Science ®Google Scholar
• Lai AY, Fatemi M, Dhasarathy A, et al. DNA methylation prevents CTCF-mediated silencing of the oncogene BCL6 in B cell lymphomas. J Exp Med. 2010;207:1939–1950.
   PubMed Web of Science ®Google Scholar
• Bernstein BE, Birney E, Dunham I, et al. An integrated encyclopedia of DNA elements in the human genome. Nature. 2012;489:57–74.
   PubMed Web of Science ®Google Scholar
• Magnenat L, Schwimmer LJ, Barbas CF. Drug-inducible and simultaneous regulation of endogenous genes by single-chain nuclear receptor-based zinc-finger transcription factor gene switches. Gene Ther. 2008;15:1223–1232.
   PubMed Web of Science ®Google Scholar
• Osipovich O, Milley R, Meade A, et al. Targeted inhibition of V(D)J recombination by a histone methyltransferase. Nat Immunol. 2004;5:309–316.
   PubMed Web of Science ®Google Scholar
• Szczepek M, Brondani V, Büchel J, et al. Structure-based redesign of the dimerization interface reduces the toxicity of zinc-finger nucleases. Nat Biotechnol. 2007;25:786–793.
   PubMed Web of Science ®Google Scholar
• Miller JC, Holmes MC, Wang J, et al. An improved zinc-finger nuclease architecture for highly specific genome editing. Nat Biotechnol. 2007;25:778–785.
   PubMed Web of Science ®Google Scholar
• Ji Q, Fischer AL, Brown CR, et al. Engineered zinc-finger transcription factors activate OCT4 (POU5F1), SOX2, KLF4, c-MYC (MYC) and miR302/367. Nucleic Acids Res. 2014;42:6158–6167.
   PubMed Web of Science ®Google Scholar
• Cong L, Zhou R, Kuo Y-C, et al. Comprehensive interrogation of natural TALE DNA-binding modules and transcriptional repressor domains. Nat Commun. 2012;3:968.
   PubMed Web of Science ®Google Scholar
• Polo JM, Dell’Oso T, Ranuncolo SM, et al. Specific peptide interference reveals BCL6 transcriptional and oncogenic mechanisms in B-cell lymphoma cells. Nat Med. 2004;10:1329–1335.
   PubMed Web of Science ®Google Scholar
• Polo JM, Juszczynski P, Monti S, et al. Transcriptional signature with differential expression of BCL6 target genes accurately identifies BCL6-dependent diffuse large B cell lymphomas. Proc Natl Acad Sci USA 2007;104:3207–3212.
   PubMed Web of Science ®Google Scholar
• Cerchietti LC, Yang SN, Shaknovich R, et al. A peptomimetic inhibitor of BCL6 with potent antilymphoma effects in vitro and in vivo. Blood. 2009;113:3397–3405.
   PubMed Web of Science ®Google Scholar
• Cerchietti LC, Lopes EC, Yang SN, et al. A purine scaffold Hsp90 inhibitor destabilizes BCL-6 and has specific antitumor activity in BCL-6-dependent B cell lymphomas. Nat Med. 2009;15:1369–1376.
   PubMed Web of Science ®Google Scholar
• Lupo A, Cesaro E, Montano G, et al. KRAB-zinc finger proteins: a repressor family displaying multiple biological functions. Curr Genomics. 2013;14:268–278.
   PubMed Web of Science ®Google Scholar
• Meylan S, Groner AC, Ambrosini G, et al. A gene-rich, transcriptionally active environment and the pre-deposition of repressive marks are predictive of susceptibility to KRAB/KAP1-mediated silencing. BMC Genomics. 2011;12:378.
   PubMed Web of Science ®Google Scholar
• Jamieson AC, Miller JC, Pabo CO. Drug discovery with engineered zinc-finger proteins. Nat Rev Drug Discov. 2003;2:361–368.
   PubMed Web of Science ®Google Scholar
• Kim H, Kim J-S. A guide to genome engineering with programmable nucleases. Nat Rev Genet. 2014;15:321–334.
   PubMed Web of Science ®Google Scholar
• Gilbert LA, Larson MH, Morsut L, et al. CRISPR-mediated modular RNA-guided regulation of transcription in eukaryotes. Cell. 2013;154:442–451.
   PubMed Web of Science ®Google Scholar
• Falahi F, Huisman C, Kazemier HG, et al. Towards sustained silencing of HER2/neu in cancer by epigenetic editing. Mol Cancer Res. 2013;11:1029–1039.
   PubMed Web of Science ®Google Scholar
• Gaj T, Guo J, Kato Y, et al. Targeted gene knockout by direct delivery of zinc-finger nuclease proteins. Nat Methods. 2012;9:805–807.
   PubMed Web of Science ®Google Scholar